HanchorBio's Trispecific Strategy Boosts HCB303's Prospects
Rethinking the Anti-TIGIT Game with HCB303 There's a fresh breeze blowing in the realm of immunotherapy, and it comes courtesy of HanchorBio's innovative trispecific approach. Now, for those of us who've been unimpressed by the underwhelming returns from anti-TIGIT trials, this new development might just stir the pot. HanchorBio's got the green light not only from the...
Continue Reading